Information Provided By:
Fly News Breaks for November 16, 2015
LLY
Nov 16, 2015 | 08:44 EDT
As noted earlier, BMO Capital upgraded Eli Lilly to Outperform from Market Perform. The firm says that the company's growth outlook has improved due to positive developments involving drugs in its pipeline. BMO expects the company to report "mostly positive" data on its drugs in 2016. Target $100.
News For LLY From the Last 2 Days
LLY
Mar 26, 2024 | 07:08 EDT
JPMorgan estimates Amgen (AMGN) without its obesity pipeline is worth $240-$250 per share and that the market is assigning $30-$40 per share of value to Maritide. While the competitive bar for Maritide is high and moving higher based on Novo Nordisk's (NVO) recent pipeline updates, the obesity market is also "unprecedented in terms of size," the analyst tells investors in a research note. The firm estimates peak sales for Maritide of $6B, equating to mid-single-digit share within the incretin space. JPMorgan believes this supports a value roughly in-line with what is reflected in Amgen's current share price. It sees a positive risk/reward scenario given the recent pullback but maintains a Neutral rating on the name with a $290 price target. The firm says Amgen is viewed as the best positioned name beyond Eli Lilly (LLY) and Novo to have a role in the obesity space.